Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 176 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07493395RecruitingPhase 2
CAR T-cell therapy for severe systemic sclerosis
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
LilleAges 18–64 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06874764Enrolling by invitation
Training with a wireless system for thinking and reaction in MS
This study tests whether a special wireless reaction training system can help improve thinking and reaction speed in people with multiple sclerosis (MS). It compares this training to standard exercises to see which works better for your brain health.
Izmir, BornovaAges 18–55 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT02869048Recruiting
Study blood and immune signals in ALS and healthy controls
This trial studies the “innate immune system” (your body’s first-line immune response) in people with ALS and in comparison groups. It may help researchers understand what drives ALS and how immune changes could relate to symptoms.
AarhusAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT00794352Recruiting
Studying immune brain and nerve conditions with tests and samples
This study looks at how immune-related brain or spinal cord illness shows up using exams, MRI scans, and sometimes a spinal fluid test (lumbar puncture), plus collected blood and other samples. It may help researchers better understand these conditions and improve future diagnosis or treatments.
Bethesda, MarylandAges 1 month–99 years - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07339540RecruitingEarly Phase 1
BCMA gene therapy for recurring autoimmune diseases
This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.
Wuhan, HubeiAges 18–65 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06732674Recruiting
Home-based care for lung disease in rheumatic conditions
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
OsloAges 18 years+ - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT07543679Recruiting
Measuring Skin Damage in Systemic Sclerosis with a Skin Sensor
This study tests a sensor device called ADHELASKIN to see if it can accurately measure skin damage in people with systemic sclerosis (SSc), a condition that hardens and tightens the skin. The goal is to find a better way to track skin changes during the disease.
Saint-Priest-en-Jarez, Pays de la Loire RegionAges 18 years+ - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT03582800RecruitingPhase 2
Sodium thiosulfate shots for abnormal calcium or bone spots
This pilot study tests a medicine called sodium thiosulfate (given as a skin shot) to treat abnormal calcium or bone formation in places they don’t belong. It’s meant for people whose condition is causing significant problems, and who are not planning surgery for the next year.
BordeauxAges 6 months+
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 176 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.